Deals this week: Istituto Biochimico Italiano Giovanni Lorenzini, Resolution Biosciences, Sanofi

8 September 2016 (Last Updated September 8th, 2016 18:30)

Istituto Biochimico Italiano Giovanni Lorenzini (IBI-Lorenzini) and Celonic AG have entered a co-development agreement to establish a reliable and substantial development platform to their clients worldwide.

Istituto Biochimico Italiano Giovanni Lorenzini (IBI-Lorenzini) and Celonic AG have entered a co-development agreement to establish a reliable and substantial development platform to their clients worldwide.

Pursuant to the agreement, the two partners will jointly indulge in the development of high-performance, GMP-compliant cell lines for research and development (R&D).

Resolution Biosciences and Leidos Biomedical Research have entered an agreement to evaluate the former’s proprietary ctDx platform chemistry and bioinformatics data analysis pipeline.

According to the agreement, Leidos Biomedical Research is responsible for evaluating liquid biopsy technologies to detect all forms of mutations from clinical specimens.

"Sanofi plans to raise gross proceeds of $948.5m through a public offering of notes, due September 2022."

The agreement enables the partners to further develop and evaluate the use of the ctDX platform in clinical trials.

Sanofi plans to raise gross proceeds of $948.5m through a public offering of notes, due September 2022. The company intends to utilise the funds for general corporate purposes.

Pharmaceutical International has raised $93m in a venture financing round led by Signet Healthcare Partners along with Athyrium Capital Management LP, Hildred Capital Partners LLC and Pharmascience Inc.

The company plans to use the funds to develop its formulation capabilities, commercial manufacturing and generic products pipeline.


Image: Sanofi plans to raise gross proceeds of $948.5m through a public offering of notes, due September 2022. Photo: courtesy of Tangopaso.